Company Filing History:
Years Active: 2025
Title: Beibei Qin: Innovator in Antibody Development
Introduction
Beibei Qin is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies for cancer treatment. His work focuses on creating targeted therapies that can improve patient outcomes.
Latest Patents
Beibei Qin holds a patent for a CLDN18.2-targeting antibody, which is a bispecific antibody designed for therapeutic use. The invention discloses antibodies that specifically target CLDN18.2, a protein expressed in certain tumor cells. This single-domain heavy-chain antibody exhibits high affinity for tumor cells and can induce significant endocytic activity. The bispecific antibody targets both CLDN18.2 and CD3, optimizing the release of common cytokines to reduce adverse effects during treatment. He has 1 patent related to this groundbreaking work.
Career Highlights
Beibei Qin is currently employed at Harbour Biomed (Shanghai) Co., Ltd. His role involves research and development of novel therapeutic antibodies. His expertise in antibody engineering has positioned him as a key player in the biotechnology sector.
Collaborations
Beibei has collaborated with notable colleagues, including Ming-jin Jheng and Yongqiang Wang. These partnerships have enhanced the research and development efforts at Harbour Biomed, leading to advancements in antibody therapies.
Conclusion
Beibei Qin's innovative work in antibody development showcases his commitment to improving cancer treatment options. His contributions to the field are significant and continue to influence the direction of biopharmaceutical research.